ABSTRACT
A commercial test (rELISA) based on a recombinant chlamydial lipopolysaccharide (LPS) antigen has been evaluated for the diagnosis of acute infections caused by Chlamydia pneumoniae (TWAR) and Chlamydia psittaci. This test and a microimmunofluorescence test (MIF) were compared in 160 patients with community-acquired pneumonia. Seventeen of nineteen cases with significant titre changes detected by rELISA were confirmed by MIF. The two remaining cases not confirmed by MIF were considered false-positive reactions. One case positive by MIF only was judged not to be a true-positive reaction. All three cases occurred in patients with Mycoplasma pneumoniae infection and may be the result of a mitogenic effect. High antibody titres have been used to indicate acute C. pneumoniae infection. We found high MIF or rELISA titres to be equally common in patients and controls; no association between the two tests was detected. An unexpected cross-reactivity between the rELISA antigen and parvovirus was observed, which might have diagnostic implications. Both MIF and rELISA detected acute C. pneumoniae and C. psittaci infection, and there was good agreement between the tests. Single serum diagnosis was generally not feasible with either MIF or rELISA.
Subject(s)
Antibodies, Bacterial/blood , Chlamydia Infections/diagnosis , Chlamydophila pneumoniae/immunology , Chlamydophila psittaci/immunology , Lipopolysaccharides/immunology , Adolescent , Adult , Aged , Aged, 80 and over , Chlamydia Infections/immunology , Complement Fixation Tests/methods , Enzyme-Linked Immunosorbent Assay , Female , Fluorescent Antibody Technique, Direct , Humans , Lipopolysaccharides/blood , Male , Middle Aged , Pneumonia, Bacterial/diagnosis , Pneumonia, Bacterial/immunologyABSTRACT
In a prospective trial of aerosolized pentamidine as secondary prophylaxis for Pneumocystis carinii pneumonia (PCP) 18 patients received 400 mg once weekly for a mean period of 15.5 months. Pentamidine aerosol was administered with an MA2 jet nebulizer. No PCP relapses were observed and no serious side effects occurred.
Subject(s)
AIDS-Related Opportunistic Infections/prevention & control , Pentamidine/therapeutic use , Pneumonia, Pneumocystis/prevention & control , Aerosols , Humans , Male , Pentamidine/administration & dosage , Pentamidine/adverse effects , Prospective StudiesABSTRACT
308 consecutive patients with severe or complicated respiratory tract infections underwent fiber-optic bronchoscopy in the search for a microbiological etiology. Protected brush specimens were used for bacterial cultures and bronchoalveolar lavage (BAL) for virus isolation and cytological examination. Herpes simplex virus (HSV) was the most commonly found pathogen and was isolated in 37 patients. 20 (54%) of them also had serological and/or cytological signs of HSV infection. 132 patients required assisted ventilation (AV) and in this group 34 (92%) of the 37 HSV positive patients were found. Isolation of HSV was significantly (p less than 0.001) associated with AV compared to patients not requiring AV. Of all patients treated with AV 26% had positive HSV isolation in conjunction with suspected acute lower respiratory infection. Coinfection with HSV and bacteria occurred in only 8 (22%) patients. HSV was more common in patients with burns (47%) compared to other patient groups such as patients with AIDS (3%) or other immunodeficiencies (9%).
Subject(s)
Herpes Simplex/diagnosis , Lung/microbiology , Pneumonia, Viral/microbiology , Acyclovir/therapeutic use , Bronchoscopy , Herpes Simplex/drug therapy , Humans , Simplexvirus/isolation & purificationABSTRACT
Since July 1987, 20 HIV-positive patients with Pneumocystis carinii pneumonia (PCP) admitted to the Department of Infectious Diseases, Malmö General Hospital, Sweden have been treated with 10 consecutive days of aerosol pentamidine as sole antimicrobial therapy in a prospective open non-controlled trial. 16 patients (80%) responded to 10 days of 400 mg aerosol pentamidine daily. One patient responded after a prolonged treatment, one patient received simultaneous trimethoprim-sulfamethoxazole due to lack of improvement during aerosol therapy. Two patients died 26 and 41 days after initiation of treatment. No systemic side effects occurred. In conclusion, we found that 10 days of aerosol pentamidine may be a safe and effective treatment of PCP. Controlled studies are needed.
Subject(s)
Acquired Immunodeficiency Syndrome/complications , Pentamidine/therapeutic use , Pneumonia, Pneumocystis/drug therapy , Administration, Inhalation , Adult , Aerosols , Humans , Male , Middle Aged , Pentamidine/administration & dosage , Pilot Projects , Pneumonia, Pneumocystis/complications , Prospective StudiesABSTRACT
In a controlled open study of 38 patients with acute pyelonephritis, treatment with fosfomycin 8 g b.i.d. was compared to treatment with ampicillin 2 g t.i.d., both for one week. The most common pathogen in both groups was Escherichia coli, susceptible to fosfomycin. However, 17% were resistant to ampicillin. The success rate was 44% in the fosfomycin treated group and 28% in the ampicillin group. The difference was not significant (p greater than 0.20). Peak concentrations of fosfomycin in serum were 395 mg/l and in tissue fluid 85 mg/l. Urine concentrations ranged from 6990 to 24,320 mg/l.
Subject(s)
Ampicillin/therapeutic use , Fosfomycin/therapeutic use , Pyelonephritis/drug therapy , Acute Disease , Fosfomycin/adverse effects , Fosfomycin/pharmacokinetics , Humans , Random AllocationABSTRACT
215 strains of Streptococcus pneumoniae isolated from blood or cerebrospinal fluid at 3 different laboratories in Sweden were serotyped by coagglutination and subtyped by the capsular reaction test. 78% of the strains belonged to serotypes which are included in or completely cross-immunogenic with serotypes included in the 14-valent vaccine while serotypes included in the 23-valent vaccine covered 89% of the isolates. Types 7F, 14 and 33F, which cannot be detected by counterimmunoelectrophoresis constituted 19% of all strains.